Tests venetoclax with azacytidine before stem cell transplant in older adults with MDS
Tests a drug combination before stem cell transplant in older adults with higher-risk myelodysplastic syndromes.
Plain-language title generated from the registry record
Registry title: VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for older adults with higher-risk myelodysplastic syndromes (MDS). It tests a conditioning treatment with venetoclax plus azacytidine before a donor stem-cell transplant.
- Age
- 70 years and older
- Sex
- Men and women can join.
- Disease stage
- Higher-risk MDS, diagnosed by the standard World Health Organization (WHO) criteria.
Main reasons for not taking part
- Active or uncontrolled infection needing systemic treatment within 14 days before enrollment
- Unstable systemic disease, including severe heart, liver, kidney or metabolic disease that needs treatment
Read by machine on 12 November 2026.
Where in China
- Navy General HospitalBeijing, ChinaContact: Liren Qian, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Navy General Hospital, Beijing
- Trial code
- NCT06471946
- Record updated
- 1 October 2024
- Original description
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.Read full original descriptionShow less
Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Inclusion: The patient should, in the investigator's opinion, be able to meet all clinical trial requirements; The patient is willing and able to adhere to the study visit schedule and other protocol requirements; The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).
Exclusion: Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment; Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.